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ABSTRACT
Fanconi anemia (FA) is a rare disease characterized by congenital defects, 
bone marrow failure, and atypically early-onset cancers. The FA proteins function 
cooperatively to repair DNA interstrand crosslinks. A major step in the activation 
of the pathway is the monoubiquitination of the FANCD2 and FANCI proteins, and 
their recruitment to chromatin-associated nuclear foci. The regulation and function 
of FANCD2 and FANCI, however, is poorly understood. In addition, how chromatin 
state impacts pathway activation is also unknown. In this study, we have examined 
the influence of chromatin state on the activation of the FA pathway. We describe 
potent activation of FANCD2 and FANCI monoubiquitination and nuclear foci 
formation following treatment of cells with the histone methyltransferase inhibitor 
BRD4770. BRD4770-induced activation of the pathway does not occur via the direct 
induction of DNA damage or via the inhibition of the G9a histone methyltransferase, 
a mechanism previously proposed for this molecule. Instead, we show that BRD4770-
inducible FANCD2 and FANCI monoubiquitination and nuclear foci formation may 
be a consequence of inhibition of the PRC2/EZH2 chromatin-modifying complex. In 
addition, we show that inhibition of the class I and II histone deacetylases leads to 
attenuated FANCD2 and FANCI monoubiquitination and nuclear foci formation. Our 
studies establish that chromatin state is a major determinant of the activation of 
the FA pathway and suggest an important role for the PRC2/EZH2 complex in the 
regulation of this critical tumor suppressor pathway.
INTRODUCTION
All organisms are continuously exposed to 
endogenous and exogenous DNA damaging agents, 
including reactive oxygen species and aldehydes from 
normal metabolic processes and UV irradiation from 
sunlight. The timely and accurate repair of DNA damage 
is essential for the maintenance of genome stability and 
organismal survival. As a consequence, prokaryotic 
and eukaryotic organisms have evolved complex and 
highly orchestrated DNA repair pathways to effectively 
repair damaged DNA. Chromatin represents the 
higher order macromolecular complex of DNA and 
histone proteins, and chromatin plasticity has become 
increasingly recognized as a major determinant of DNA 
damage recognition, signaling, and repair [1–3]. The 
nucleosome is the fundamental subunit of chromatin 
and exhibits plasticity via compositional alteration, 
translational repositioning, and the posttranslational 
modification of histone tails. Histone tails are subject 
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to a wide variety of posttranslational modifications 
including acetylation, methylation, phosphorylation, 
and ubiquitination [4]. Histone acetylation homeostasis 
is mediated by histone acetyltransferases (HATs), e.g. 
TIP60/KAT5, and deacetylases (HDACs), e.g. HDAC1 
and HDAC2. Underscoring the importance of histone 
acetylation in DNA repair, key roles for TIP60/KAT5, 
HDAC1, and HDAC2 in the maintenance of genome 
stability have been established [5–7].
Fanconi anemia (FA) is a rare autosomal and 
X-linked genetic disease characterized by congenital 
defects, bone marrow failure, and increased cancer risk 
in early adulthood [8]. FA is caused by mutation of any 
one of 21 genes. The FA proteins function primarily in 
the repair of DNA interstrand crosslinks (ICLs), lesions 
that block the replication and transcription machineries, 
which lead to structural and numerical chromosome 
aberrations if repaired erroneously [8–11]. A central step 
in the activation of the FA pathway is the site-specific 
monoubiquitination of the FANCD2 and FANCI proteins 
[12–14]. Monoubiquitinated FANCD2 and FANCI 
localize to discrete sites within chromatin where they 
are hypothesized to promote the recruitment of several 
structure-specific endonucleases, including FAN1 
(FANCD2-associated nuclease 1) and FANCQ/ERCC4 
[15–18]. While FANCD2 and FANCI function primarily 
within chromatin, the contribution of chromatin plasticity, 
and specifically, the effects of changes in histone tail 
posttranslational modifications, on their activation and 
function have yet to be determined. Furthermore, while 
chromatin remodeling at DNA double-strand breaks 
(DSBs) has been extensively studied [1–3], very little 
is known about the role of chromatin remodeling in the 
context of ICL repair.
In this study we have examined the influence of 
chromatin structure on the activation of the FA pathway. 
Specifically, we have examined the effects of histone 
methyltransferase (HMT), demethylase (HDM), and 
deacetylase (HDAC) inhibitors on FANCD2 and FANCI 
monoubiquitination and their assembly into discrete 
nuclear foci. We describe potent activation of FANCD2 
and FANCI monoubiquitination in chromatin, and 
enhanced FANCD2 and FANCI nuclear foci formation, 
following cellular exposure to the HMT inhibitor 
BRD4770. BRD4770-induced activation of the pathway 
does not appear to occur via the direct induction of DNA 
damage per se, or via the inhibition of the G9a histone 
methyltransferase, a mechanism previously proposed for 
this molecule [19]. In contrast, our results suggest that 
BRD4770-induced activation of the pathway may be a 
consequence of inhibition of PRC2 (Polycomb Repressive 
Complex 2) and, specifically, its catalytic HMT EZH2. In 
addition, we demonstrate that inhibition of class I and II 
HDACs with trichostatin A (TSA) and vorinostat (SAHA) 
leads to attenuated ICL-inducible FANCD2 and FANCI 
monoubiquitination and nuclear foci formation. Our 
results establish that chromatin plasticity, and in particular 
the posttranslational modification of histone tails, is 
a critical determinant in the activation of the FA tumor 
suppressor pathway.
RESULTS
Activation of FANCD2 and FANCI 
monoubiquitination by the HMTi BRD4770
To explore the effects of global alterations in 
histone methylation on the activation of the FA pathway, 
we exposed the transformed osteosarcoma cell line 
U2OS and the nontransformed telomerase (hTERT)-
immortalized line BJ-TERT to the HMT inhibitors (HMTi) 
BRD4770 and BIX01294 and the HDM inhibitors (HDMi) 
GSK-J1 and PBIT, and examined FANCD2 and FANCI 
monoubiquitination. BRD4770 is a S-adenosylmethionine 
(SAM) mimetic and competitive inhibitor of PRC2/
EZH2 and G9a [19–21]. BIX01294 is a non-SAM 
mimetic selective inhibitor of G9a [21]. Treatment with 
BRD4770 resulted in a marked increase in FANCD2 
and FANCI monoubiquitination in both U2OS and BJ-
TERT cells, even in the absence of the ICL-inducing 
agent mitomycin C (MMC) (Figure 1A and 1B, lane 3). 
Indeed, the ratio of FANCD2-Ub to FANCD2 (L:S ratio) 
was higher in cells treated with BRD4770 alone than 
in cells treated with MMC alone (Figure 1A and B, 
compare lanes 2 and 3). BRD4770-induced activation 
of FANCD2 monoubiquitination also occurred in a 
concentration-dependent manner (Figure 1C). In contrast, 
no major effects on levels of spontaneous or ICL-inducible 
FANCD2/I monoubiquitination were observed for the 
other inhibitors tested, other than a slight increase in the 
FANCD2/I L:S ratios following treatment of BJ-TERT 
cells with GSK-J1 (Figure 1B).
BRD4770 promotes FANCD2 chromatin 
localization and nuclear foci formation
Next, we examined the effects of BRD4770 
treatment on the localization of FANCD2 to chromatin 
and its assembly into nuclear foci. Cells were incubated 
in the absence or presence of BRD4770, both with and 
without MMC, and whole-cell (W), soluble cytoplasmic 
and nuclear (S), and chromatin-enriched (C) protein 
lysates were prepared and analyzed by immunoblotting. 
We observed greatly elevated levels of monoubiquitinated 
FANCD2 and FANCI in the chromatin fraction of cells 
treated with BRD4770 alone (Figure 2A, compare 
lanes 3 and 9). In addition, using immunofluorescence 
microscopy (IF), we analyzed FANCD2 nuclear foci 
formation, an indicator of the localization of FANCD2 to 
sites of damaged DNA in chromatin [12, 22], following 
treatment with BRD4770 alone and following combined 
treatment with BRD4770 and MMC. We observed a 
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striking increase in the percentage of nuclei exhibiting 
greater than 5 FANCD2 foci in both U2OS and BJ-
TERT cells following BRD4770 treatment (Figure 
2B and Supplementary Figure 1A and 1B). Levels of 
FANCD2 nuclear foci formation in cells treated with 
BRD4770 alone were comparable to that observed 
following MMC treatment (Supplementary Figure 1A 
and 1B). These results identify BRD4770 as a major 
inducer of FANCD2 monoubiquitination and nuclear foci 
formation and strongly suggest that changes in histone 
methylation status are a critical determinant in the 
activation of the FA pathway. Consistent with BRD4770 
functioning via the modification of chromatin structure, 
we observed a distinct change in the staining pattern of 
the heterochromatin marker HP1ɑ following BRD4770 
treatment (Supplementary Figure 1C).
BRD4770-inducible activation of the FA pathway 
does not occur via direct induction of DNA 
damage, increased expression of the FA core 
complex, or changes in cell cycle progression
One possible explanation for BRD4770-induced 
activation of FANCD2 and FANCI monoubiquitination 
and nuclear foci formation is that BRD4770 induces 
DNA damage directly. To test this hypothesis, we 
examined levels of the phosphorylated H2A variant 
H2AX (γH2AX), a well-established biomarker of 
DNA DSB formation [23], in cells treated with and 
without BRD4770. No differences in the number of 
nuclei exhibiting γH2AX foci were observed between 
untreated cells and cells treated with BRD4770, both 
in the absence or presence of MMC (Figure 3A and 
Figure 1: The HMTi BRD4770 induces the monoubiquitination of FANCD2 and FANCI. (A) and (B), U2OS (A) and BJ-
TERT (B) cells were incubated in the absence (NT) or presence of 10 μM BRD4770, 2.5 μM BIX01294, 5 μM GSK-J1 and 1 μM PBIT, 
with (+) and without (-) 200 nM mitomycin C (MMC) for 24 h. Whole-cell lysates were prepared and immunoblotted with anti-FANCD2, 
anti-FANCI, and anti-ɑ-Tubulin antibodies. (C) U2OS cells were incubated with the indicated concentrations of BRD4770 and BIX01294 
for 24 h, and whole-cell lysates were immunoblotted with anti-FANCD2, anti-FANCI, and anti-ɑ-Tubulin antibodies. L:S Ratio, ratio of 
monoubiquitinated to nonubiquitinated FANCD2 or FANCI.
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Supplementary Figure 2). Similar results were observed 
in both U2OS and BJ-TERT cells (Figure 3A and 
Supplementary Figure 2). U2OS cells have a highly 
unstable karyotype, with recurrent breakage-fusion-
bridge cycles most likely contributing to the elevated 
spontaneous levels of γH2AX nuclear foci formation 
observed in these cells (Supplementary Figure 2). While 
we observed a faint γH2AX signal for cells treated with 
BRD4770 alone via immunoblotting, this level was 
markedly lower than that observed following exposure 
to the topoisomerase type II inhibitor etoposide (VP-16), 
a well known inducer of DNA DSBs, and no different to 
that observed following GSK-J1 treatment (Figure 3B). 
We also examined levels of RPA S4/8 phosphorylation, 
a marker of single-stranded DNA [24], following 
BRD4770 exposure. While MMC treatment led to a 
strong increase in levels of RPA pS4/8, no increase in 
levels above that of untreated cells was observed for 
BRD4770 (Figure 3C). We also examined the effects of 
BRD4770 treatment on levels of the FA core complex 
proteins FANCA and UBE2T/FANCT. UBE2T/FANCT 
is the FANCD2 E2 ubiquitin-conjugating enzyme [25]. 
Levels of both proteins decreased following BRD4770 
treatment (Figure 3C). Decreased levels of FANCA were 
also observed following exposure of HCT116 p53+/+ and 
p53-/- cells to BRD4770 (see Supplementary Figure 3D). 
Similarly, we observed a reduction in levels of the 
USP1 de-ubiquitinating enzyme following BRD4770 
treatment (Figure 3C). Concomitant reductions in the 
levels of FANCA, UBE2T/FANCT, and USP1 cannot 
explain the observed BRD4770-induced FANCD2 and 
FANCI monoubiquitination and nuclear foci formation. 
Figure 2: The HMTi BRD4770 induces FANCD2 chromatin localization and nuclear foci formation. (A) U2OS cells were 
incubated in the absence (NT) or presence of 10 μM BRD4770 with (+) and without (-) 200 nM mitomycin C (MMC) for 24 h. Whole-cell 
lysates (W) and soluble nuclear and cytoplasmic (S) and chromatin-enriched (C) fractions were prepared and immunoblotted with anti-
FANCD2, anti-FANCI, anti-H2A, and anti-ɑ-Tubulin antibodies. (B) U2OS cells were incubated with (+) and without (-) 200 nM MMC 
in the absence (NT) or presence of 10 μM BRD4770 for 24 h. Cells were fixed and stained with rabbit polyclonal anti-FANCD2 antibody 
(green) and counterstained with DAPI (blue), and the number of nuclei with >5 FANCD2 foci were scored. At least 300 nuclei were scored 
for each treatment. Representative immunofluorescence microscopy images are shown.
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We observed an increase in levels of phosphorylated 
CHK1 S345 following treatment with BRD4770, 
albeit to a lesser extent than that observed following 
MMC treatment (Figure 3C). Finally, we examined the 
effects of BRD4770 treatment on cell cycle progression. 
Following exposure to BRD4770 for 24 h, we observed 
an increase in the percentage of cells in S-phase at all 
concentrations of BRD4770 examined (Figure 3D). 
However, following exposure to BRD4770 for 48 and 
72 h, where maximal induction of FANCD2 and FANCI 
monoubiquitination was observed (see Figure 4B), the 
cell cycle stage profiles did not differ substantially from 
that of untreated cells (Figure 3D). Taken together, these 
results argue that BRD4770-induced activation of the FA 
pathway does not appear to be a consequence of direct 
induction of DNA damage, alterations in expression of 
the FANCD2 core monoubiquitination proteins, or major 
changes to cell cycle progression.
Figure 3: BRD4770-induced activation of the FA pathway does not occur via the direct induction of DNA damage 
or altered cell cycle progression.  (A) BJ-TERT cells were incubated with (+) and without (-) 200 nM mitomycin C (MMC) in 
the absence (NT) or presence of 10 μM BRD4770 for 24 h. Cells were fixed and stained with mouse monoclonal anti-γH2AX antibody 
and counterstained with DAPI, and the number of nuclei with >5 γH2AX foci were scored. At least 300 nuclei were scored for each 
treatment and this experiment was performed three times with similar results. Error bars represent the standard errors of the means from 
three independent experiments. (B) BJ-TERT cells were incubated with (+) and without (-) 0.4 μM etoposide (VP-16), in the absence or 
presence of 10 μM BRD4770, 5 μM GSK-J1 and 2.5 μM BIX01294, for 24 h. Whole-cell lysates were immunoblotted with anti-γH2AX 
and anti-PCNA (loading control) antibodies. (C) U2OS cells were incubated in the absence (NT) or presence of 200 nM MMC or 5 and 10 
μM BRD4770 for 24 h. Whole-cell lysates were prepared and immunoblotted with anti-FANCD2, anti-FANCA, anti-UBE2T, anti-USP1, 
anti-CHK1 pS345, anti-RPA, anti-RPA pS4/8, and anti-ɑ-Tubulin antibodies. L:S Ratio, ratio of monoubiquitinated to nonubiquitinated 
FANCD2; RBI, relative band intensity. (D) U2OS cells were incubated in the absence or presence of 2, 5, and 10 μM BRD4770 for 24, 48, 
or 72 h. Cells were fixed in ice-cold ethanol, stained with propidium iodide, and analyzed by flow cytometry. Cell cycle stage distributions 
were determined using FlowJo v10.2.
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BRD4770-induced activation of the FA pathway 
may occur via inhibition of the PRC2 complex
BRD4770 is a SAM mimetic and a structural 
analogue of BIX01338, a non-selective HMT inhibitor 
with similar IC50 values against the G9a and SUV39H1 
HMTs [19–21]. Therefore, we next treated U2OS cells 
with varying concentrations of BIX01338 to determine 
if we would observe activation of the FA pathway, 
similar to that observed for BRD4770. Surprisingly, we 
did not observe any appreciable induction of FANCD2 
or FANCI monoubiquitination following treatment with 
BIX01338 for acute (24 h) (Supplementary Figure 3A) 
or extended periods (up to 10 d) (results not shown). 
BRD4770 is a methyl ester analogue of BRD9539, and 
previous experiments with BRD9539 have shown that 
it exhibits specificity for G9a and PRC2 (Polycomb 
Repressive Complex 2) [19]. EZH2 is the catalytic 
HMT of PRC2, and catalyzes the deposition of the 
transcriptionally repressive mark H3K27me3 [26]. 
Therefore, to determine if BRD4770-induced activation 
of FANCD2 monoubiquitination might be a specific 
consequence of G9a and/or EZH2 inhibition, we treated 
cells with the DZNep and UNC0646 HMT inhibitors: 
DZNep treatment has been reported to lead to cellular 
depletion of EZH2 [27], while UNC0646 is a potent 
inhibitor of G9a [28]. We observed modest induction 
of FANCD2 and FANCI monoubiquitination following 
exposure to 2 and 4 μM DZNep (Figure 4A). Considerable 
cell toxicity was observed at 10 μM DZNep (results not 
shown). Under these conditions, we did not observe a 
decrease in levels of EZH2 expression. However, reduced 
Figure 4: BRD4770-induced activation of the FA pathway may occur via inhibition of the PRC2 complex. (A) U2OS cells 
were incubated in the absence (NT) or presence of BRD4770, DZNep, UNC0646, and DZNep and UNC0646 combined (4 μM each) for 24 
h. Whole-cell lysates were prepared and immunoblotted with anti-FANCD2, anti-FANCI, anti-EZH2, and anti-ɑ-Tubulin antibodies. (B) 
U2OS cells were incubated in the absence or presence of 2, 5, and 10 μM BRD4770 for 24, 48, or 72 h. Whole-cell lysates were prepared 
and immunoblotted with anti-FANCD2, anti-FANCI, anti-CHK1 pS345, anti-EZH2, anti-H3K27me3, and anti-ɑ-Tubulin antibodies. L:S 
Ratio, ratio of monoubiquitinated to nonubiquitinated FANCI; or FANCD2 RBI, relative band intensity.
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levels of EZH2 were observed following incubation with 
DZNep, and BRD4770 to a lesser extent, for 4 and 8 days 
(Supplementary Figure 3B). In contrast to DZNep, no 
induction of FANCD2/I monoubiquitination was observed 
following treatment with UNC0646, and combined 
DZNep/UNC0646 treatment resulted in considerable cell 
death (Figure 4A and results not shown). Consistent with 
these findings, we also observed a modest yet statistically 
significant increase in FANCD2 nuclear foci formation 
in cells treated with DZNep and not with UNC0646 
(Supplementary Figure 3C). We note that the degree of 
DZNep-induced FANCD2/I monoubiquitination was 
experimentally variable, most likely a consequence of its 
pleiotropic nature. To further explore the potential role of 
EZH2 and H3K27me3 in BRD4770-inducible FANCD2/I 
monoubiquitination, we exposed U2OS cells to BRD4770 
for 24, 48, and 72 h and examined levels of EZH2 and 
H3K27me3 (Figure 4B). We observed reductions in 
levels of H3K27me3 following treatment with higher 
concentrations of BRD4770 for 72 h, when induction of 
FANCD2 monoubiquitination was maximal (Figure 4B). 
Under the same conditions, we did not observe any 
significant reductions in EZH2 levels (Figure 4B). 
Similarly, we also observed a modest reduction in levels of 
H3K27me3 in HCT116 p53-/- cells treated with BRD4770 
for 24 h and a more pronounced reduction in HeLa cells 
treated with BRD4770 for 72 h (Supplementary Figures 
3D and 3E). We again observed induction of CHK1 pS345 
upon exposure to higher concentrations of BRD4770 for 
extended periods (Figure 4B).
EPZ-6438-mediated inhibition of PRC2/
EZH2 leads to activation of FANCD2 
monoubiquitination
To further analyze the role of PRC2 and EZH2 in 
the activation of the FA pathway, cells were treated with 
EPZ-6438, an EZH2-specific inhibitor [29, 30], and 
FANCD2 and FANCI monoubiquitination and nuclear 
foci formation were analyzed. In MCF10A cells, a 
spontaneously-immortalized, nontransformed, mammary 
epithelial line, EPZ-6438 treatment led to a pronounced 
increase in FANCD2 and FANCI protein levels, FANCD2 
and FANCI monoubiquitination, and FANCD2 nuclear 
foci formation (Figure 5A and Supplementary Figure 4). 
Interestingly, EPZ-6438 treatment led to an increase in 
levels of EZH2, possibly a cellular response to chemical 
inhibition of EZH2, and an overall reduction in levels of 
H3K27me3 (Figure 5A). EPZ-6438 treatment also resulted 
in increased FANCD2 monoubiquitination in isogenic 
HCT116 p53+/+ and p53-/- cells (Figure 5B) and HeLa cells 
(Figure 5C). In contrast to MCF10A, HeLa, and HCT116, 
we did not detect increased FANCD2 monoubiquitination 
in U2OS cells treated with EPZ-6438 (results not shown). 
Taken together, our results suggest that BRD4770-induced 
activation of the FA pathway may occur via inhibition of 
the PRC2 complex, and specifically EZH2 HMT activity, 
and a consequent decrease in levels of H3K27me3.
Inhibition of class I and II HDACs attenuates 
activation of the FA pathway
To investigate the influence of histone acetylation 
state on the activation of the FA pathway, we next 
examined the effects of the class I and II HDAC inhibitors 
trichostatin A (TSA) and vorinostat (SAHA) on FANCD2 
and FANCI monoubiquitination and nuclear foci 
formation. Interestingly, for HeLa cells, we did not observe 
any appreciable differences in the levels of spontaneous 
or ICL-inducible FANCD2 or FANCI monoubiquitination 
when cells were treated with TSA or SAHA (Figure 6A 
and 6B). In contrast, when BJ-TERT cells were treated 
with TSA or SAHA, we observed a marked reduction 
in the levels of ICL-inducible FANCD2 and FANCI 
monoubiquitination (Figure 6C and 6D). TSA and SAHA 
treatment led to a reduction in ICL-inducible CHK1 S345 
phosphorylation in both lines examined (Figure 6). In 
contrast, incubation with TSA and SAHA did not lead to 
any observable changes in levels of ICL-inducible CHK2 
pT68 (Figure 6). We observed a concentration-dependent 
increase in the levels of H4K16ac following treatment 
with TSA and SAHA confirming their inhibition of histone 
deacetylation (Figure 6). We also observed a reduction 
in spontaneous and ICL-inducible FANCD2 nuclear 
foci formation in both HeLa and BJ-TERT cells treated 
with TSA or SAHA (Figure 7A–7D). Consistent with 
our immunoblotting results, this effect was particularly 
striking for BJ-TERT cells with a lesser effect observed 
for HeLa cells (Figure 7A–7D).
The FA pathway is a major determinant of cellular 
sensitivity to ICL-inducing agents. Therefore we next 
examined if treatment with HDAC I and II inhibitors 
would sensitize cells to the cytotoxic effects of MMC. 
Indeed, even at the low concentrations of inhibitors 
examined, treatment with the HDAC I and II inhibitors 
sodium butyrate (NaB) and TSA sensitized BJ-TERT 
cells to the cytotoxic effects of MMC over a range of 
MMC concentrations (Figure 8A and 8B). In contrast, 
treatment with nicotinamide (NAM), an inhibitor of the 
NAD+ (nicotinamide adenine dinucleotide)-dependent 
sirtuin (class III) family of HDACs, did not impact 
cellular sensitivity to MMC (Figure 8C). Taken together, 
our results indicate that HDAC1 and HDAC2 positively 
regulate activation of the FA pathway and that cellular 
sensitivity to ICL-inducing agents, which are widely used 
in cancer chemotherapy, may be increased via HDAC1/2 
inhibition.
DISCUSSION
In this study, we have established that chromatin 
state is an important determinant in the activation of 
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the FA pathway. Specifically, we have established that 
treatment with the HMTi BRD4770 and inhibition of the 
class I and II HDACs strongly impacts activation of the FA 
pathway. BRD4770 was recently discovered in a focused 
screen of a 2-substituted benzimidazole library [19]. While 
in in vitro biochemical assays, BRD9539, the carboxylic 
acid derivative of BRD4770, effectively inhibited both 
G9a and PRC2/EZH2 in a concentration-dependent 
manner, these studies concluded that BRD4770 functions 
primarily via the inhibition of G9a [19]. However, in 
our experiments, while BRD4770 robustly promoted 
FA pathway activation, several G9a-specific inhibitors - 
including BIX01294 and UNC0646 - failed to promote 
FA pathway activation. Our results suggest that BRD4770 
does not act primarily via G9a inhibition, and that G9a 
does not play a significant role in the regulation of the FA 
pathway. Instead, our findings suggest that BRD4770 may 
exert its cellular effects, at least in part, via the inhibition 
Figure 5: Activation of FANCD2 monoubiquitination following treatment with the EZH2 inhibitor EPZ-6438. (A-C) 
MCF10A (A), HCT116 p53+/+ and p53-/- (B), and U2OS (C) cells were treated with the indicated concentrations of the EZH2-specific 
inhibitor EPZ-6438 for 24 h (A and B) or 24, 48, and 72 h (C). Whole-cell lysates were prepared and immunoblotted with the indicated 
antibodies. L.E., light exposure; D.E., dark exposure; L:S Ratio, ratio of monoubiquitinated to nonubiquitinated FANCI; or FANCD2 RBI, 
relative band intensity.
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of PRC2/EZH2, and that PRC2/EZH2 may play an 
important role in the regulation of the activation of the FA 
pathway. Several findings support this model: Exposure 
to BRD4770 resulted in reduced levels of H3K27me3 - 
the transcriptionally repressive mark deposited by PRC2/
EZH2 [26] - in several cell models. Modest activation of 
FANCD2 monoubiquitination and nuclear foci formation 
was observed following treatment with the PRC2/EZH2 
inhibitor DZNep [27]. However, while DZNep was 
initially reported to be selective for PRC2/EZH2 [27], as a 
S-adenosylhomocysteine hydrolase inhibitor, DZNep can 
also affect global histone methylation patterns [31]. This 
led us to examine the effects of inhibition of EZH2 with 
the SAM-competitive inhibitor EPZ-6438. EPZ-6438 is 
a potent and selective EZH2 inhibitor with an inhibition 
constant (Ki) of 2.5 nM. EPZ-6438 is 35-fold and >4,500-
fold more selective for EZH2 than EZH1 and 14 other 
HMTs examined [32]. In four out of five lines examined 
in this study, EPZ-6438 treatment led to an increase in 
levels of FANCD2 monoubiquitination. The mechanism(s) 
by which inhibition of PRC2/EZH2 and decreased global 
levels of H3K27me3 would lead to activation of the FA 
pathway remain to be clearly elucidated. Recent studies 
in the silkworm Bombyx mori have shown that PRC2-
mediated H3K27me3 increases following exposure to UV 
irradiation [33]. One possibility is that, upon exposure 
to DNA damaging agents, transcription may need to be 
halted at loci that have incurred DNA damage. An inability 
to catalyze H3K27me3 and arrest transcription could 
lead to the formation of co-transcriptional RNA-DNA 
hybrids (R-loops). An important role for the FA proteins 
in the repair of R-loops has recently been established 
[34, 35]. However, our γH2AX and RPA pS4/8 results 
strongly suggest a DNA damage-independent mode of 
action for BRD4770. An alternative hypothesis is that 
BRD4770 treatment - possibly via both G9a and PRC2/
Figure 6: Inhibition of class I and II HDACs attenuates FANCD2 and FANCI monoubiquitination in BJ-TERT cells. 
(A) and (B), HeLa cells were pre-treated with the indicated concentrations of trichostatin A (TSA) (A) or vorinostat (SAHA) (B) for 4 h, 
followed by co-incubation with (+) and without (-) 200 nM MMC for a further 20 h. Whole-cell lysates were prepared and immunoblotted 
with anti-FANCD2, anti-FANCI, anti-CHK1 pS345, anti-CHK2 pT68, anti-H4K16ac, and anti-ɑ-Tubulin antibodies. (C) and (D), BJ-
TERT cells were treated identically to that described for HeLa cells above. L:S Ratio, ratio of monoubiquitinated to nonubiquitinated 
FANCD2 or FANCI.
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EZH2 inhibition - leads to the general establishment of a 
transcriptionally permissive chromatin state, which leads 
to the recruitment of factors that promote homologous 
recombination (HR) DNA repair, such as FANCD2 
and FANCI [13, 36]. Consistent with this hypothesis, 
Aymard et al have recently shown that HR factors are 
enriched at transcriptionally active chromatin [37]. It 
is important to note, however, that BRD4770-induced 
Figure 7: Inhibition of class I and II HDACs attenuates FANCD2 nuclear foci formation. (A) and (B), HeLa cells were 
treated with the indicated concentrations of trichostatin A (TSA) (A) or vorinostat (SAHA) (B) in the absence (NT) or presence (MMC) 
of 200 nM mitomycin C (MMC) for 24 h. Cells were fixed and stained with rabbit polyclonal anti-FANCD2 antibody and counterstained 
with DAPI, and the number of nuclei with >5 FANCD2 foci were scored. *, P < 0.05; **, P < 0.01; ***, P < 0.001, with comparison to 
untreated cells. (C) and (D), BJ-TERT cells were treated identically to that described for HeLa cells above. At least 300 nuclei were scored 
for each treatment and these experiments were performed three times with similar results. Error bars represent the standard errors of the 
means from three independent experiments.
Figure 8: Inhibition of class I and II HDACs sensitizes cells to the cytotoxic effects of mitomycin C.  BJ-TERT cells were 
exposed to the indicated concentrations of mitomycin C (MMC) in the absence or presence of (A) 5 mM sodium butyrate (NaB), (B) 331 
nM trichostatin A (TSA), or (C) 10 mM nicotinamide (NAM) and cellular proliferation was determined using the CellTiter 96® AQueous 
One Solution Cell Proliferation (MTS) assay. Error bars represent the standard errors of the means from three independent experiments.
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activation of the FA pathway most likely does not occur 
solely via the inhibition of PRC2/EZH2: BRD4770 
induces FANCD2/I monoubiquitination more robustly 
than the EZH2-specific inhibitor EPZ-6438, and EPZ-
6438 treatment results in more pronounced decreases in 
levels of H3K27me3. Therefore, other mechanisms are 
likely to contribute to the observed effects of BRD4770. 
In our study, we also detected increased phosphorylation 
of CHK1 S345 following BRD4770 exposure, indicating 
activation of the ATR-CHK1 checkpoint-signaling 
pathway. Numerous studies have indicated an important 
role for this pathway in signaling aberrant changes in 
chromatin structure [38–40]. One possibility is that 
BRD4770-induced changes in chromatin state lead 
to activation of ATR, phosphorylation of CHK1 and 
monoubiquitination of FANCD2, leading to activation 
of the intra-S-phase checkpoint. These findings are 
consistent with a large body of evidence linking the 
ATR-CHK1 signaling pathway to the activation of the FA 
pathway [41–44]. However, while BRD4770 treatment 
for 24 h did lead to an accumulation of cells in S-phase, 
exposure to BRD4770 for longer periods - when levels 
of phosphorylated CHK1 S345 and monoubiquitinated 
FANCD2 were maximal - did not appear to result in 
an overt S-phase arrest. Further experiments will be 
required to determine the relationship between changes in 
chromatin state, activation of the ATR-CHK1-FANCD2 
axis and maintenance of the intra-S-phase checkpoint.
Here, we have also established that chemical 
inhibition of class I and II HDACs leads to attenuation 
of FANCD2 and FANCI monoubiquitination in BJ-
TERT cells, with a less pronounced effect in HeLa cells, 
and significant reductions in FANCD2 nuclear foci 
formation in both HeLa and BJ-TERT cells. FANCD2/I 
monoubiquitination and nuclear foci are not strictly 
coupled: Usp1-/- murine cells exhibit increased Fancd2 
monoubiquitination in the absence of nuclear foci 
formation [45]. Thus, under the conditions examined, 
our findings point to an important role for histone 
deacetylation in facilitating the efficient activation of 
the FA pathway. Previous studies in the budding yeast 
S. cerevisiae, have shown that valproic acid (VPA), 
a class I and II HDACi, inhibits Mec1 (orthologue of 
human ATR) signaling [46]. This is consistent with 
our observation of reduced ICL-inducible CHK1 S345 
phosphorylation following HDAC inhibition with SAHA 
and TSA. Taken together with our BRD4770 findings, our 
results indicate that the ATR-CHK1 signaling pathway 
responds to changes in chromatin structure, and that 
phosphorylation and activation of CHK1 correlates with 
monoubiquitination and activation of FANCD2.
Several studies have established that, during the 
very early stages of DSB repair - seconds to minutes - 
a transient repressive chromatin state is first established, 
characterized by the spreading of HP1 and H3K9me2/3 
[47]. The multisubunit NuRD repressor complex is rapidly 
recruited to sites of DNA damage where it promotes 
histone deacetylation and chromatin remodeling [48–50]. 
This may be necessary to restrict transcription in the 
immediate vicinity of the damaged site and to promote 
the recruitment of repair factors [47]. A failure to rapidly 
establish this transient repressive chromatin state would 
be predicted to lead to inefficient activation of DNA repair 
pathways, as we have observed following ICL treatment 
and HDAC inhibition. In contrast, a failure to catalyze 
H3K27me3 upon exposure to BRD4770 or EPZ-6438 may 
lead to persistent, constitutively open/relaxed chromatin, 
which in turn may promote the inadvertent activation of 
repair mechanisms, as previously shown [51].
In summary, our results establish that chromatin 
state is an important determinant of the activation of the 
FA pathway. Our findings also suggest that combination 
chemotherapy comprising ICL-inducing agents and 
HDAC inhibitors may be an effective strategy for 
certain cancers. Recent studies have identified three 
functional modules within the FA core complex: the 
FANCB-FANCL-FAAP100 module, which provides the 
essential monoubiquitination catalytic activity, and the 
FANCA-FANCG-FAAP20 and FANCC-FANCE-FANCF 
modules, which are thought to promote the recruitment of 
the core complex to chromatin [52, 53]. The majority of 
FA patients harbor mutations in the FANCA and FANCG 
genes, and FANCD2/I monoubiquitination is defective 
in >95% of FA patients [54]. Based on our findings, 
it is conceivable that the chromatin recruitment of the 
monoubiquitination catalytic module could be promoted 
via chemical modification of chromatin state, raising the 
prospect of epigenetics-based therapeutic approaches for 
certain FA complementation groups.
MATERIALS AND METHODS
Cell culture
The osteosarcoma cell line U2OS, the cervical 
carcinoma cell line HeLa, and the hTERT-immortalized 
BJ-TERT cells were grown in DMEM supplemented with 
15% v/v fetal bovine serum, 2 mM L-glutamine, 50 U/mL 
penicillin, and 50 μg/mL streptomycin. HCT116 p53+/+ and 
p53-/- cells were grown in McCoy’s 5A medium containing 
the same supplements [55]. MCF10A mammary epithelial 
cells were grown in DMEM F12 supplemented with 
5% v/v horse serum, 20 ng/ml epidermal growth factor, 
0.5 mg/ml hydrocortisone, 100 ng/ml cholera toxin, 10 μg/
ml insulin, 2 mM L-glutamine, 50 U/mL penicillin, and 50 
μg/mL streptomycin.
Chemicals
The structures of all chemicals used in this study are 
shown in Supplementary Figure 5. The following chemicals 
were used: BRD4770 (histone methyltransferase inhibitor 
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VI) (C
25
H
23
N3O3) (382194; EMD Millipore), BIX01294 
(C
28
H38N6O2
.3HCl.xH
2
O) (B9311; Sigma), GSK-J1 (histone 
lysine demethylase inhibitor VII) (C
22
H
23
N5O2) (420204; 
EMD Millipore), PBIT (histone lysine demethylase inhibitor 
IX) (C14H11NOS) (505299; EMD Millipore), UNC0646 
(C36H59N7O2) (SML0633; Sigma), BIX01338 (C32H24F3N
3O6
.xH
2
O) (B5313; Sigma), DZNep (3-Deazaneplanocin 
A) (C
12
H14N4O3) (13828; Cayman Chemical), EPZ-6438 
(Tazemetostat) (C34H44N4O4) (S7128; Selleckchem), SAHA 
(Vorinostat) (C14H20N2O3) (SML0061; Sigma), Trichostatin 
A (TSA) (C17H22N2O3) (T1952; Sigma), Mitomycin C 
(MMC) (C15H18N4O5) (BP25312; Fisher Scientific), and 
Etoposide (VP-16) (C
29
H
32
O13) (E1383; Sigma).
Immunoblotting and antibodies
For immunoblotting analysis, cell pellets were washed 
in PBS and lysed in 2% w/v SDS, 50 mM Tris-HCl, 10 mM 
EDTA. Proteins were resolved on NuPage 3-8% w/v Tris-
Acetate or 4-12% w/v Bis-Tris gels (Invitrogen) and 
transferred to polyvinylidene difluoride (PVDF) membranes. 
The following antibodies were used: mouse monoclonal sera 
against γH2AX (05-636; Millipore), HDAC1 (5356; Cell 
Signaling), HDAC2 (5113; Cell Signaling), HP1α (05-689; 
Millipore), PCNA (sc-56; Santa Cruz Biotechnology), 
RPA (NA18; Calbiochem), and α-tubulin (MS-581-PO; 
Neomarkers), rabbit monoclonal serum against CHK1 
pS345 (2348; Cell Signaling), and rabbit polyclonal sera 
against CHK2 pT68 (2661; Cell Signaling), EZH2 (5246S; 
Cell Signaling), FANCA (ABP6201; Cascade), FANCD2 
(NB100-182; Novus Biologicals), FANCI (A301-254A; 
Bethyl Laboratories), H2A (07-146; Millipore), H3K27me3 
(9733P; Cell Signaling), H4K16ac (07-329; Millipore), RPA 
pS4/8 (A300-245A; Bethyl), USP1 (a kind gift from Tony 
T. Huang, New York University), and UBE2T (A301-874A; 
Bethyl).
Immunofluorescence microscopy
For immunofluorescence microscopy (IF) analysis, 
cells were seeded in 4-well tissue culture slides (BD 
Falcon) in the presence or absence of drug(s) for 24 h. 
Soluble cellular proteins were pre-permeabilized with 
0.3% v/v Triton X-100 and cells were fixed in 4% w/v 
paraformaldehyde and 2% w/v sucrose at 4°C followed by 
permeabilization in 0.3% v/v Triton X-100 in PBS. Fixed 
cells were blocked for 30 minutes in antibody dilution 
buffer (5% v/v goat serum, 0.1% v/v NP-40, in PBS) 
and incubated with primary antibody for 1 h. Cells were 
washed three times in PBS, as well as permeabilization 
buffer, and incubated for 30 min at room temperature with 
an Alexa Fluor 488-conjugated secondary antibody and the 
slides were counterstained and mounted in vectashield plus 
4’6-diamidine-2-phenylindole dihydrochloride (DAPI) 
(Vector Laboratories). Nuclear foci were scored using a 
Zeiss AxioImager.A1 upright epifluorescence microscope 
with AxioVision LE 4.6 image acquisition software. 
Primary antibodies used for IF were anti-FANCD2 
(NB100-182; Novus Biologicals), anti-FANCI (A300-
212A; Bethyl Laboratories), and anti-γH2AX (05-636; 
Millipore). Statistical significance was determined using 
paired two-tailed Student’s t-test analysis.
Chromatin fractionation
Cells were plated at density of 3 x 106 cells in 15 cm2 
dishes. The following day, cells were treated with 200 nM 
MMC for 24 h. Cells were harvested and resuspended in 
ice-cold PBS. A portion of the pellet was retained as a 
whole cell lysate (W). The remaining pellet was lysed on 
ice in cytoskeletal buffer (CSK) (300 mM Sucrose, 100 
mM NaCl, 3 mM MgCl
2
, 0.5% v/v Triton-X-100, 1 mM 
EGTA, 10 mM PIPES, pH 6.8). The supernatant, containing 
soluble cytoplasmic and nuclear proteins, was collected as 
the soluble fraction (S). The remaining pellet, containing 
chromatin-associated and nuclear insoluble proteins (C), 
and the whole-cell lysate pellet, were lysed in 2% SDS lysis 
buffer with sonication for 10 s at 10% amplitude using a 
Fisher Scientific Model 500 Ultrasonic Dismembrator.
Cell proliferation assay
Cells were plated at a density of 10,000 cells/well 
in 96-well dishes, incubated in the absence or presence of 
drug(s) for 48 h. CellTiter 96® AQueous One Solution Reagent 
(MTS) (Promega) was added directly to the wells, incubated 
for a further 2 h, and the absorbance at 490 nm was measured 
using a 96-well Bio-Rad 680 microplate reader.
Cell-cycle analysis
Cells were plated at a density of 1x106 cells in 10 cm2 
dishes. The following day, cells were incubated in the absence 
or presence of 2, 5, and 10 μM BRD4770 for 24, 48, and 72 
h. Cells were resuspended in 0.1 mL PBS and fixed by adding 
1 mL ice-cold methanol. Cells were washed in PBS and 
incubated in 50 μg/mL propidium iodide (PI) (Sigma) and 
30 U/mL RNase A for 10 min at 37°C, followed by analysis 
using a BD FACSVerse flow cytometer. The percentages of 
cells in G1, S, and G2/M were determined by analyzing PI 
histograms with FlowJo V10.2 software.
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